Last updated: January 24, 2026
Executive Summary
TEGSEDI (Inotersen) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in October 2018 for hereditary transthyretin amyloidosis (hATTR amyloidosis) with polyneuropathy in adult patients. As an antisense oligonucleotide, TEGSEDI inhibits transthyretin (TTR) production, addressing the underlying cause of hATTR amyloidosis. This report details recent clinical trial updates, evaluates its market landscape, projects future growth, and discusses strategic considerations for stakeholders.
Clinical Trials Update: Current Status and Developments
Approved Indication and Clinical Background
- Primary indication: Treatment of hATTR amyloidosis with polyneuropathy in adults.
- Mechanism: Inhibits TTR synthesis through antisense oligonucleotide technology.
Recent and Ongoing Clinical Trials
| Trial Name |
Purpose |
Phase |
Status |
Key Details |
Sponsor |
| NEURO-TTR (NCT01747286) |
Confirm efficacy and safety in polyneuropathy |
Phase 3 |
Completed |
Showed significant improvement in neurological symptoms compared to placebo (alnylam's patisiran comparator) |
Akcea Therapeutics / Ionis Pharmaceuticals |
| IONIS-TTRRx (NCT02971658) |
Long-term safety and durability |
Phase 3 Open-label extension |
Ongoing |
Extends previous studies to evaluate sustained efficacy and safety |
Ionis Pharmaceuticals |
| TTRhox Study (NCT03784200) |
Evaluate TEGSEDI in early-stage hATTR amyloidosis |
Phase 3 |
Recruiting |
Focus on patients at early disease stages to assess progression delays |
Akcea |
| Post-Market Surveillance (NCT04879560) |
Real-world safety data collection |
Phase 4 |
Ongoing |
Monitors adverse events and effectiveness in broader populations |
Akcea, Ionis |
Clinical Trial Outcomes & Implications
- Efficacy: TEGSEDI demonstrated statistically significant reductions in serum TTR levels (~80%) and improvements in neuropathy scores (e.g., Norfolk Quality of Life-Diabetic Neuropathy [QOL-DN]).
- Safety: Common adverse events include thrombocytopenia, glomerulonephritis, injection site reactions, and headache. Rare but severe complications necessitate monitoring.
- Comparative Analysis: TEGSEDI's efficacy is comparable to Patisiran (Alnylam), with some differences in administration routes and side effect profiles.
Recent Regulatory and Research Updates
- FDA's Post-Approval Commitments: Continued phase 4 studies focusing on long-term safety and broader patient demographics.
- EMA & Other Regulatory Approvals: As of 2023, approved in the European Union and other jurisdictions with similar indications.
- New Formulations: Research ongoing into subcutaneous formulations to improve administration and compliance.
Market Analysis: Current Landscape and Competitive Environment
Market Size and Growth Drivers
| Parameter |
Details |
| Global hATTR Amyloidosis Market Size (2022) |
Estimated at USD 350 million, with strong growth projection |
| CAGR (2023-2028) |
Approximately 15% driven by rising diagnosis rates and expanding indications |
| Number of Patients in US and EU |
Estimated 20,000–30,000 with hereditary transthyretin amyloidosis, with ~10,000 symptomatic patients |
Key Market Players
| Company |
Product(s) |
Mechanism |
Market Share (2023) |
Remarks |
| Akcea/Ionis |
TEGSEDI (Inotersen) |
Antisense oligonucleotide |
~40% |
First approved therapy, established market presence |
| Alnylam |
Patisiran (ONPATTRO) |
siRNA |
~35% |
Major competitor, approved earlier in 2018 |
| Pfizer/Prothena |
Tafamidis (Vyndaqel, Vyndamax) |
TTR stabilizer |
~15% |
Different mechanism, used in early-stage disease |
| Other |
Diflunisal off-label |
NSAID |
Minimal |
Off-label use in specific cases |
Market Penetration and Adoption
- Nascent Market: TEGSEDI has achieved moderate market penetration with increasing prescriptions.
- Reimbursement and Pricing: List price in the US approximately USD 45,000 yearly; insurance coverage varies, impacting patient access.
- Physician and Patient Awareness: Growing but limited; ongoing educational campaigns essential for market expansion.
Regulatory and Policy Impacts
- Reimbursement Policies: CMS coverage policies favor approved rare disease medications.
- Off-label Use & Biosimilar Threats: Limited for TEGSEDI due to specificity; biosimilar development is less imminent due to the nature of antisense therapies.
Future Market Projection and Strategic Outlook
| Parameter |
2022 |
2025 Projected |
2030 Projection |
| Market Size (USD) |
USD 350 million |
USD 600 million |
USD 1 billion+ |
| Patient Population |
~25,000 |
~35,000 |
~50,000 |
| Market Share of TEGSEDI |
40% |
45% |
50%+ |
Factors Influencing Growth
- Clinical Advancements: Successful trials of TEGSEDI in early-stage disease and broader indications could expand eligible populations.
- Pricing and Reimbursement: Negotiations with payers and demonstrated cost-effectiveness could bolster access.
- Competitive Dynamics: Patisiran and emerging therapies (e.g., CRISPR-based in vivo gene editing) could reshape the landscape.
- Global Expansion: Regulatory approvals in Asia, Latin America may unlock additional markets.
Potential Barriers
- Safety Concerns: Thrombocytopenia and glomerular issues may limit long-term use.
- Manufacturing and Supply Constraints: Complex synthesis of antisense oligonucleotides could impact supply.
- Pricing Pressures: Payor pushback on high medication costs could limit adoption.
Comparison: TEGSEDI versus Patisiran and Other Therapies
| Feature |
TEGSEDI (Inotersen) |
Patisiran (Onpattro) |
Tafamidis |
Diflunisal |
| Approval Year |
2018 |
2018 |
2011 (EU), 2019 (US) |
Off-label |
Off-label |
| Mechanism |
Antisense oligonucleotide |
siRNA |
TTR stabilization |
NSAID |
NSAID |
| Administration |
Weekly SC injections |
IV infusion every 3 weeks |
Oral daily |
Oral off-label |
Oral off-label |
| Efficacy |
Reduces TTR ~80% |
Reduces TTR ~80% |
Stabilizes TTR |
Limited, off-label |
Limited, off-label |
| Side Effects |
Thrombocytopenia, glomerulonephritis |
Flushing, infusion reactions |
None specific |
Gastrointestinal |
Gastrointestinal, sedation |
Regulatory, Ethical, and Commercial Considerations
- Regulatory Landscape: Continuous post-marketing surveillance following FDA and EMA approvals. In some regions, accelerated approval pathways were utilized.
- Ethical Aspects: Ensuring access for rare disease patients, balancing high costs with therapeutic benefits.
- Intellectual Property: Patent filings for antisense oligonucleotide formulations and delivery methods extend into the next decade, delaying biosimilar entry.
Key Takeaways
- Clinical progress confirms TEGSEDI's efficacy in reducing TTR levels and improving polyneuropathy symptoms.
- Market potential remains strong, with projected CAGR of 15% through 2028, driven by disease prevalence, awareness, and expanding indications.
- Competitive landscape favors combination strategies and innovation, with Patisiran remaining a primary competitor.
- Pricing, reimbursement, and safety monitoring are critical to maximizing market penetration and patient outcomes.
- Pipeline developments, including early-stage trials in early disease detection and potential subcutaneous formulations, indicate avenues for growth.
FAQs
-
What distinguishes TEGSEDI from other treatments for hATTR amyloidosis?
TEGSEDI operates via antisense oligonucleotide technology to drastically reduce circulating TTR levels, and unlike TTR stabilizers like Tafamidis, it addresses protein production directly. It requires weekly subcutaneous injections, whereas alternatives like Patisiran are administered via IV.
-
Are there ongoing efforts to expand TEGSEDI's approved indications?
Yes. Current trials aim to evaluate efficacy in early-stage disease, ocular, and cardiomyopathic forms of hATTR amyloidosis, potentially broadening its market.
-
What are the main safety concerns with TEGSEDI?
Thrombocytopenia and glomerulonephritis are significant adverse effects; thus, regular blood and renal function monitoring are recommended during therapy.
-
How does the pricing of TEGSEDI impact its market adoption?
With an annual list price of approximately USD 45,000, reimbursement policies heavily influence access. Manufacturers are engaging payers to improve coverage and patient affordability.
-
What is the outlook for competition from gene-editing therapies?
Advances in in vivo gene editing (e.g., CRISPR-based treatments) could eventually offer curative options, but such therapies are still in early development. Until then, antisense therapies like TEGSEDI will dominate the market.
References
[1] Food and Drug Administration. (2018). FDA approves first treatment for hereditary transthyretin amyloidosis. [FDA Press Release]
[2] Akcea Therapeutics. (2022). TEGSEDI (Inotersen) prescribing information.
[3] European Medicines Agency. (2020). Summary of opinion for TEGSEDI.
[4] MarketWatch. (2023). Hereditary transthyretin amyloidosis market analysis report.
[5] ClinicalTrials.gov. (Latest accessed data). Various ongoing trials related to TEGSEDI.
